Terran Orbital starts trading on the NYSE with $200 million in outstanding spacecraft orders

Terran Orbital starts trading on the NYSE with 0 million in outstanding spacecraft orders


Spacecraft manufacturer Terran Orbital began trading on the New York Stock Exchange on Monday after closing its SPAC merger, going public with over $200 million in outstanding orders.

Terran trades under the ticker LLAP — a reference to the Star Trek saying “live long and prosper” – with shares previously listed under the special purpose acquisition company Tailwind Two Acquisition Corp.

Shares of Terran swung in its trading debut: The stock rose as much as 15% at the open, before falling as much as 19%, and then changing direction again to finish the day up 7.6% at $11.80 a share.

Terran joins a trend of space companies going public through SPAC deals, such as Virgin Galactic, Astra, Rocket Lab, Planet and more. But Terran co-founder and CEO Marc Bell told CNBC that he believes his company’s foundation sets it apart.

“We look at a lot of these space SPACs that have gone out and a lot of them weren’t businesses that should have gone public,” Bell said. “We, on the other hand, have real revenues, real pipeline, real backlog, real customers.”

Closing its merger nets Terran with $255 million in gross proceeds, with $29.4 million from Tailwind Two as well as a $50.8 million PIPE round — or private investment in public equity — which included investors AE Industrial Partners, Beach Point Capital and Lockheed Martin. The remaining capital came from $175.3 million in debt financing through Francisco Partners, Beach Point Capital and Lockheed Martin.

“We’re using that money to expand — basically hiring and training of new people and adding new facilities,” Bell said.

Terran booked $25 million in revenue in 2020, which grew to more than $40 million last year. The company has contracts to build dozens of satellites for customers including NASA and the Pentagon, with its revenue backlog growing from $68 million last year to more than $200 million currently.

Headquartered in Boca Raton, Florida, the company has announced plans to expand its satellite manufacturing capability by building a 660,000 square-foot facility near Cape Canaveral and leasing a 60,000 square-foot facility in Irvine, California. With more than 300 employees, the company is building off its consolidation of two former subsidiaries, satellite manufacturer Tyvak and imagery specialist PredaSAR.

“Our manufacturing business is unique, because it’s truly a recurring revenue business,” Bell said. “For the U.S. government, it’s far cheaper for them to build a constellation of satellites and keep refreshing it, and keep refreshing it with current technology, then build one ‘juicy target’ in space.”

Terran is both building spacecraft for other customers and working on its own system of 96 Earth imagery satellites, which Bell described as “Earth observation 3.0.” The satellites would combine two types of imagery collection technology, optical and synthetic aperture radar, Bell said, so that Terran can “overlay the data” and provide more in-depth analysis to customers.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More